{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T06:22:31Z","timestamp":1648880551753},"reference-count":14,"publisher":"Japanese Society of Toxicologic Pathology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Toxicol Pathol"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1293\/tox.2021-0007","type":"journal-article","created":{"date-parts":[[2021,6,6]],"date-time":"2021-06-06T22:07:15Z","timestamp":1623017235000},"page":"367-371","source":"Crossref","is-referenced-by-count":0,"title":["Karnovsky\u2019s fixative prevents artifacts appearing as vacuolation derived from          tissue processing in kidneys treated with antisense oligonucleotide"],"prefix":"10.1293","volume":"34","author":[{"given":"Hironobu","family":"Nishina","sequence":"first","affiliation":[{"name":"Safety Research Laboratories, Sohyaku, Innovative              Research Division, Mitsubishi Tanabe Pharma Corporation, 2-26-1 Muraoka-Higashi,              Fujisawa, Kanagawa 251-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Sakairi","sequence":"additional","affiliation":[{"name":"Safety Research Laboratories, Sohyaku, Innovative              Research Division, Mitsubishi Tanabe Pharma Corporation, 2-26-1 Muraoka-Higashi,              Fujisawa, Kanagawa 251-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akane","family":"Kashimura","sequence":"additional","affiliation":[{"name":"Safety Research Laboratories, Sohyaku, Innovative              Research Division, Mitsubishi Tanabe Pharma Corporation, 2-26-1 Muraoka-Higashi,              Fujisawa, Kanagawa 251-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Sato","sequence":"additional","affiliation":[{"name":"Safety Research Laboratories, Sohyaku, Innovative              Research Division, Mitsubishi Tanabe Pharma Corporation, 2-26-1 Muraoka-Higashi,              Fujisawa, Kanagawa 251-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao","family":"Mizukawa","sequence":"additional","affiliation":[{"name":"Safety Research Laboratories, Sohyaku, Innovative              Research Division, Mitsubishi Tanabe Pharma Corporation, 2-26-1 Muraoka-Higashi,              Fujisawa, Kanagawa 251-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhei","family":"Ozawa","sequence":"additional","affiliation":[{"name":"Safety Research Laboratories, Sohyaku, Innovative              Research Division, Mitsubishi Tanabe Pharma Corporation, 2-26-1 Muraoka-Higashi,              Fujisawa, Kanagawa 251-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satomi","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Safety Research Laboratories, Sohyaku, Innovative              Research Division, Mitsubishi Tanabe Pharma Corporation, 2-26-1 Muraoka-Higashi,              Fujisawa, Kanagawa 251-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"121","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1.  Rinaldi              C, and                Wood              MJA. Antisense            oligonucleotides: the next frontier for treatment of neurological            disorders. Nat Rev Neurol. 14:            9\u201321. 2018.","DOI":"10.1038\/nrneurol.2017.148"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2.  Uemura              Y, and                Kobayashi              K. Targeting            murine alveolar macrophages by the intratracheal administration of locked nucleic acid            containing antisense oligonucleotides. Drug Deliv.            26: 803\u2013811. 2019.","DOI":"10.1080\/10717544.2019.1648589"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3.  Bennett              CF. Therapeutic            antisense oligonucleotides are coming of age. Annu Rev            Med. 70: 307\u2013321.            2019.","DOI":"10.1146\/annurev-med-041217-010829"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4.  Frazier              KS. Antisense            oligonucleotide therapies: the promise and the challenges from a toxicologic            pathologist\u2019s perspective. Toxicol Pathol.            43: 78\u201389. 2015.","DOI":"10.1177\/0192623314551840"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5.  Engelhardt              JA. Comparative            renal toxicopathology of antisense oligonucleotides. Nucleic            Acid Ther. 26: 199\u2013209.            2016.","DOI":"10.1089\/nat.2015.0598"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6.  Frazier              KS,                Sobry              C,                Derr              V,                Adams              MJ,                Besten              CD,                De Kimpe              S,                Francis              I,                Gales              TL,                Haworth              R,                Maguire              SR,                Mirabile              RC,                Mullins              D,                Palate              B,                Doorten              YPS,                Ridings              JE,                Scicchitano              MS,                Silvano              J, and                Woodfine              J.            Species-specific inflammatory responses as a primary component for the            development of glomerular lesions in mice and monkeys following chronic administration            of a second-generation antisense oligonucleotide. Toxicol            Pathol. 42: 923\u2013935.            2014.","DOI":"10.1177\/0192623313505781"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7.  Sewing              S,                Gubler              M,                G\u00e9rard              R,                Avignon              B,                Mueller              Y,                Braendli-Baiocco              A,                Odin              M, and                Moisan              A. GalNAc            conjugation attenuates the cytotoxicity of antisense oligonucleotide drugs in renal            tubular cells. Mol Ther Nucleic Acids.            14: 67\u201379. 2019.","DOI":"10.1016\/j.omtn.2018.11.005"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8.  Kakiuchi-Kiyota              S,                Koza-Taylor              PH,                Mantena              SR,                Nelms              LF,                Enayetallah              AE,                Hollingshead              BD,                Burdick              AD,                Reed              LA,                Warneke              JA,                Whiteley              LO,                Ryan              AM, and                Mathialagan              N. Comparison            of hepatic transcription profiles of locked ribonucleic acid antisense oligonucleotides:            evidence of distinct pathways contributing to non-target mediated toxicity in            mice. Toxicol Sci. 138:            234\u2013248. 2014.","DOI":"10.1093\/toxsci\/kft278"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9.  Hagedorn              PH,                Yakimov              V,                Ottosen              S,                Kammler              S,                Nielsen              NF,                H\u00f8g              AM,                Hedtj\u00e4rn              M,                Meldgaard              M,                M\u00f8ller              MR,                \u00d8rum              H,                Koch              T, and                Lindow              M. Hepatotoxic            potential of therapeutic oligonucleotides can be predicted from their sequence and            modification pattern. Nucleic Acid Ther.            23: 302\u2013310. 2013.","DOI":"10.1089\/nat.2013.0436"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10.  Burdick              AD,                Sciabola              S,                Mantena              SR,                Hollingshead              BD,                Stanton              R,                Warneke              JA,                Zeng              M,                Martsen              E,                Medvedev              A,                Makarov              SS,                Reed              LA,                Davis              JW              2nd, and                Whiteley              LO. Sequence            motifs associated with hepatotoxicity of locked nucleic acid--modified antisense            oligonucleotides. Nucleic Acids Res.            42: 4882\u20134891. 2014.","DOI":"10.1093\/nar\/gku142"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11.  Henry              SP,                Johnson              M,                Zanardi              TA,                Fey              R,                Auyeung              D,                Lappin              PB, and                Levin              AA. Renal            uptake and tolerability of a 2\u2032-O-methoxyethyl modified antisense oligonucleotide (ISIS            113715) in monkey. Toxicology. 301:            13\u201320. 2012.","DOI":"10.1016\/j.tox.2012.06.005"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12.  Henry              SP,                Bolte              H,                Auletta              C, and                Kornbrust              DJ. Evaluation            of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study            in cynomolgus monkeys. Toxicology.          120: 145\u2013155. 1997.","DOI":"10.1016\/S0300-483X(97)03661-5"},{"key":"13","unstructured":"13.  Drug Approval                Package              FDA . Kynamro (mipomersen          sodium) Injection, Application No. 203568, 29 Jan. 2013, Pharmacology          Reviews, p9, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/203568Orig1s000PharmR.pdf          (Accessed Dec. 2020)"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14.  Monteith              DK, and                Levin              AA. Synthetic            oligonucleotides: the development of antisense therapeutics.            Toxicol Pathol. 27:          8\u201313. 1999.","DOI":"10.1177\/019262339902700103"}],"container-title":["Journal of Toxicologic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tox\/34\/4\/34_2021-0007\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T04:11:04Z","timestamp":1633147864000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tox\/34\/4\/34_2021-0007\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1293\/tox.2021-0007","relation":{},"ISSN":["0914-9198","1881-915X"],"issn-type":[{"value":"0914-9198","type":"print"},{"value":"1881-915X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"article-number":"2021-0007"}}